FDA Approves Roche CDx for Gastric and Gastroesophageal Junction Cancer Treatment
Roche’s VENTANA CLDN18 RxDx Assay identifies CLDN18 protein expression in gastric and gastroesophageal junction cancer patients.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
